ロード中...
Does TMB impact the effectiveness of TKIs in EGFR-mutant NSCLC?
Patients with EGFR-mutant NSCLC achieve variable benefit from targeted therapy, and biomarkers to predict degree of benefit are not in clinical use. EGFR-mutant cancers with high tumor mutational burden demonstrate poorer outcomes on EGFR targeted therapy. Investigation into the mechanisms underlyin...
保存先:
| 出版年: | Clin Cancer Res |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6359945/ https://ncbi.nlm.nih.gov/pubmed/30190372 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-2368 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|